Gastrointestinal Neuroendocrine Tumours: A Single-Centre Experience

[1] Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review. World J Gastrointest Oncol. 2014;6(8):301–310. SalyersWJ VegaKJ MunozJC TrotmanBW TanevSS Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review World J Gastrointest Oncol 2014 6 8 301 310 Search in Google Scholar

[2] Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008;13(12):1255–1269. PinchotSN HolenK SippelRS ChenH Carcinoid tumors Oncologist 2008 13 12 1255 1269 Search in Google Scholar

[3] Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–1864. RindiG KlimstraDS Abedi-ArdekaniB AsaSL BosmanFT BrambillaE A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal Mod Pathol 2018 31 12 1770 1864 Search in Google Scholar

[4] Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol. 2010;105(12):2563–2569. EllisL ShaleMJ ColemanMP Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971 Am J Gastroenterol 2010 105 12 2563 2569 Search in Google Scholar

[5] Altekruse SF, Rosenfeld GE, Carrick DM, Pressman EJ, Schully SD, Mechanic LE, et al. SEER cancer registry biospecimen research: yesterday and tomorrow. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2681–2687. AltekruseSF RosenfeldGE CarrickDM PressmanEJ SchullySD MechanicLE SEER cancer registry biospecimen research: yesterday and tomorrow Cancer Epidemiol Biomarkers Prev 2014 23 12 2681 2687 Search in Google Scholar

[6] Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and pathology: toward strengthening the critical relationship. Am J Surg Pathol. 2016;40(12):e94–e102. DugganMA AndersonWF AltekruseS PenberthyL ShermanME The Surveillance, Epidemiology, and End Results (SEER) Program and pathology: toward strengthening the critical relationship Am J Surg Pathol 2016 40 12 e94 e102 Search in Google Scholar

[7] Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009;23(3):288–295. YuJB GrossCP WilsonLD SmithBD NCI SEER public-use data: applications and limitations in oncology research Oncology (Williston Park) 2009 23 3 288 295 Search in Google Scholar

[8] Scherubl H, Streller B, Stabenow R, Herbst H, Hopfner M, Schwertner C, et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19(47):9012–9019. ScherublH StrellerB StabenowR HerbstH HopfnerM SchwertnerC Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany World J Gastroenterol 2013 19 47 9012 9019 Search in Google Scholar

[9] Pavel M, Oberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860. PavelM ObergK FalconiM KrenningEP SundinA PerrenA Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2020 31 7 844 860 Search in Google Scholar

[10] Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14(8):471–482. ScottAT HoweJR Management of small bowel neuroendocrine tumors J Oncol Pract 2018 14 8 471 482 Search in Google Scholar

[11] McCarthy DM. Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship? Int J Mol Sci. 2020;21(2):662. McCarthyDM Proton pump inhibitor use, hypergastrinemia, and gastric carcinoids—what is the relationship? Int J Mol Sci 2020 21 2 662 Search in Google Scholar

[12] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. DasariA ShenC HalperinD ZhaoB ZhouS XuY Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncol 2017 3 10 1335 1342 Search in Google Scholar

[13] Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, et al. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8(3):4935–4947. WuL FuJ WanL PanJ LaiS ZhongJ Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study Oncotarget 2017 8 3 4935 4947 Search in Google Scholar

[14] Estrozi B, Bacchi CE. Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases. Clinics (Sao Paulo). 2011;66(10):1671–1675. EstroziB BacchiCE Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases Clinics (Sao Paulo) 2011 66 10 1671 1675 Search in Google Scholar

[15] Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19(12):991–1002. OronskyB MaPC MorgenszternD CarterCA Nothing but NET: a review of neuroendocrine tumors and carcinomas Neoplasia 2017 19 12 991 1002 Search in Google Scholar

[16] Nozari N, Nikfam S, Nikmanesh A, Mohammadnejad M, Sotoudehmanesh R, Zamani F, et al. Clinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from Iran. Middle East J Dig Dis. 2014;6(3):151–155. NozariN NikfamS NikmaneshA MohammadnejadM SotoudehmaneshR ZamaniF Clinical and pathological features of non-functional neuroendocrine tumors of pancreas: a report from Iran Middle East J Dig Dis 2014 6 3 151 155 Search in Google Scholar

[17] Zeng YJ, Liu L, Wu H, Lai W, Cao JZ, Xu HY, et al. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution. Asian Pac J Cancer Prev. 2013;14(10):5775–5781. ZengYJ LiuL WuH LaiW CaoJZ XuHY Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine tumors: analysis from a single-institution Asian Pac J Cancer Prev 2013 14 10 5775 5781 Search in Google Scholar

[18] Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg. 2004;240(1):117–122. MaggardMA O’ConnellJB KoCY Updated population-based review of carcinoid tumors Ann Surg 2004 240 1 117 122 Search in Google Scholar

[19] Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. ModlinIM LyeKD KiddM A 5-decade analysis of 13,715 carcinoid tumors Cancer 2003 97 4 934 959 Search in Google Scholar

[20] Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol. 2001;12(9):1295–1300. QuaedvliegPF VisserO LamersCB Janssen-HeijenML TaalBG Epidemiology and survival in patients with carcinoid disease in The Netherlands An epidemiological study with 2391 patients. Ann Oncol 2001 12 9 1295 1300 Search in Google Scholar

[21] Gkolfinopoulos S, Tsapakidis K, Papadimitriou K, Papamichael D, Kountourakis P. Chromogranin A as a valid marker in oncology: clinical application or false hopes? World J Methodol. 2017;7(1):9–15. GkolfinopoulosS TsapakidisK PapadimitriouK PapamichaelD KountourakisP Chromogranin A as a valid marker in oncology: clinical application or false hopes? World J Methodol 2017 7 1 9 15 Search in Google Scholar

[22] Cesar D, Zanatto RM, da Silva MV, Golcalves R, de Mello EL, de Jesus JP. Colon and rectum neuroendocrine tumors: experience of the National Cancer Institute in Brazil. Arq Bras Cir Dig. 2013;26(1):36–39. CesarD ZanattoRM da SilvaMV GolcalvesR de MelloEL de JesusJP Colon and rectum neuroendocrine tumors: experience of the National Cancer Institute in Brazil Arq Bras Cir Dig 2013 26 1 36 39 Search in Google Scholar

[23] Sansone A, Lauretta R, Vottari S, Chiefari A, Barnabei A, Romanelli F, et al. Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors. Cancers (Basel). 2019;11(8):1113. SansoneA LaurettaR VottariS ChiefariA BarnabeiA RomanelliF Specific and non-specific biomarkers in neuroendocrine gastroenteropancreatic tumors Cancers (Basel) 2019 11 8 1113 Search in Google Scholar

[24] Tang H, Lu W, Li B, Meng X, Dong J. Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: a meta-analysis. Medicine (Baltimore). 2016;95(35):e4621. TangH LuW LiB MengX DongJ Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: a meta-analysis Medicine (Baltimore) 2016 95 35 e4621 Search in Google Scholar

[25] Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241(5):715–22, discussion 22–24. PawlikTM ScogginsCR ZorziD AbdallaEK AndresA EngC Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases Ann Surg 2005 241 5 715 22 discussion 22–24. Search in Google Scholar

[26] Habal N, Sims C, Bilchik AJ. Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol. 2000;75(4):310–316. HabalN SimsC BilchikAJ Gastrointestinal carcinoid tumors and second primary malignancies J Surg Oncol 2000 75 4 310 316 Search in Google Scholar

[27] Dhruv S, Anwar S, Polavarapu A, Liliane D. Gastric carcinoid: the invisible tumor! Cureus. 2021;13(2):e13556. DhruvS AnwarS PolavarapuA LilianeD Gastric carcinoid: the invisible tumor! Cureus 2021 13 2 e13556 Search in Google Scholar